Work

Adjuvant androgen deprivation (AD) +/- mitoxantrone + prednisone (MP) in patients with high-risk prostate cancer (PC) post radical prostatectomy (RP): Phase III intergroup trial S9921.

Year: 2017

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2017.35.15_suppl.5019

Authors: Maha Hussain, Catherine M. Tangen, Ian Murchie Thompson, Gregory P. Swanson, David Peter Wood, Wael Sakr, Nancy Ann Dawson, Naomi B. Haas, Thomas W. Flaig, Tanya B. Dorff, Daniel W. Lin, E. David Crawford, David I. Quinn, Nicholas J. Vogelzang, L. Michael Glode

Institutions: Northwestern University, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Fred Hutch Cancer Center, The University of Texas at San Antonio Health Science Center, Wayne State University, Georgetown University Medical Center, Georgetown Lombardi Comprehensive Cancer Center, Abramson Cancer Center, University of Colorado Cancer Center, University of Southern California, University of Washington, University of Colorado Denver, USC Norris Comprehensive Cancer Center, Comprehensive Cancer Centers of Nevada

Language: English

Topic: Prostate Cancer Diagnosis and Treatment

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2890062953

Cites:

Cited by:

Related to: 10